Sanctuary Advisors LLC Has $1.16 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sanctuary Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,915 shares of the biopharmaceutical company’s stock after purchasing an additional 357 shares during the quarter. Sanctuary Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $1,157,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP increased its position in Alnylam Pharmaceuticals by 99.3% during the 4th quarter. Capital Performance Advisors LLP now owns 877 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 437 shares during the period. Allworth Financial LP increased its position in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares during the period. Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $41,529,000. Principal Securities Inc. boosted its stake in Alnylam Pharmaceuticals by 881.0% in the fourth quarter. Principal Securities Inc. now owns 1,187 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 1,066 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Alnylam Pharmaceuticals by 87.2% in the fourth quarter. Blue Trust Inc. now owns 865 shares of the biopharmaceutical company’s stock valued at $204,000 after buying an additional 403 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ALNY shares. Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Raymond James lifted their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $303.83.

Insider Activity

In other news, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,986 shares of company stock worth $20,397,849 over the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 1.5 %

Shares of ALNY stock opened at $245.20 on Wednesday. The company has a market cap of $31.74 billion, a P/E ratio of -112.99 and a beta of 0.35. The stock has a 50 day simple moving average of $254.21 and a two-hundred day simple moving average of $262.72. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.